Global Orphan Drugs Market to Reach $855.3 Billion by 2030

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

 | Source: ReportLinker ReportLinker

New York, March 06, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Orphan Drugs Industry" - https://www.reportlinker.com/p06051495/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Orphan Drugs Market to Reach $855.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Orphan Drugs estimated at US$260.2 Billion in the year 2022, is projected to reach a revised size of US$855.3 Billion by 2030, growing at aCAGR of 16% over the period 2022-2030. Biologics, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$548.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Biologics segment is readjusted to a revised 14.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $76.1 Billion, While China is Forecast to Grow at 15.2% CAGR

The Orphan Drugs market in the U.S. is estimated at US$76.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$145.5 Billion by the year 2030 trailing a CAGR of 15.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.9% and 13% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Select Competitors (Total 18 Featured)
- AbbVie Inc.
- Actelion Pharmaceuticals Ltd.
- Alexion Pharmaceuticals Inc.
- Amgen Inc.
- AstraZeneca Plc.
- Bayer AG
- Biogen Inc.
- BioMarin Pharmaceutical Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corp.
- CEL-SCI Corporation
- Concordia International Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genzyme Corp.,
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Serono SA
- Novartis AG
- Pfizer Inc.
- Recordati S.p.A.
- Sanofi SA
- Shire Plc.
- Vertex Pharmaceuticals


Read the full report: https://www.reportlinker.com/p06051495/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
A Prelude
Recent Market Activity
Increasing Adoption of Orphan Drugs by Manufacturers
The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry
Major Orphan Drugs Legislations Worldwide
Orphan Drugs Market on a Rapid Growth Trajectory
Select Major Organizations Dealing with Rare Diseases in the
US, Canada, and EU
Incentives for Orphan Drug Designation Products in the US, EU,
and Japan
Market Challenges
Obstacles for Conducting Orphan Drug Research
Competition
Orphan Drugs Remain Strong in the Pharmaceutical Pipeline
Important Orphan Drugs in Pipeline
Orphan Drugs - Global Key Competitors Percentage Market Share
in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS
AbbVie, Inc. (USA)
Actelion Pharmaceuticals Ltd. (Switzerland)
Alexion Pharmaceuticals, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca Plc. (UK)
Bayer AG (Germany)
Biogen Inc. (USA)
BioMarin Pharmaceutical Inc. (USA)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Celgene Corp. (USA)
CEL-SCI Corporation (USA)
Concordia International Corp. (Canada)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Johnson & Johnson (USA)
Merck & Co., Inc. (USA)
Merck Serono International S.A. (Germany)
Merck Serono International S.A. (Germany)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Recordati S.p.A. (Italy)
Orphan Europe (France)
Shire Plc. (Ireland)
Sanofi SA (France)
Genzyme Corp. (USA)
Vertex Pharmaceuticals (USA)

3. MARKET TRENDS & DRIVERS
Regulatory Incentives - A Push in the Right Direction
Growing Unmet Medical Needs - Fulfilling the Gap
Rising Incidence of Rare Forms of Cancer - Opportunities Galore
Select Orphan Drugs for Cancer
Rise in Incidence of Renal Cell Carcinoma
Unmet Needs in AML
Aging Population Offers Growth Potential
Pre-Symptomatic Screening to Expand Market Base
Asia?s Rising Awareness and Growing Population to Drive Sales
Drug Repurposing Provides Therapies for Rare Diseases
The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges
Interest of Major Pharmaceutical Firms Signal a Shift in
Commercial Dynamics
Mergers and Acquisitions Drive Market Growth
Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016
Growing Scrutiny over Skyrocketing Prices
Orphan Drugs with High Prices: 2016
Medical Advancements Foster Growth
Full Reimbursements Critical for Spurring Uptake of High-Priced
Orphan Drugs
Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs
Strong Market Potential for Ultra-Orphan Drugs for Amyloid
Light-chain Amyloidosis
Increasing Patient Engagement - The PAG Trend
Gene Therapy and Bioprocessing Preferred over Chronic Therapies
Companies Developing Gene Therapies
International Collaboration - The Way Forward
CNS Therapeutics to Gain Focus in the Orphan Drugs Market
Manufacturers Target Orphan Indications to Curtail Competition
in Broader Indications
Manufacturers Use Orphan Disease to Target Larger Therapeutic
Indications
Treating Autism - The Next Big Thing?
Sequencing Technology - The New Research Tool for Orphan Drugs
Innovations in Biotechnology - A Boon for Orphan Drug Research
Aging Gene Linked to Myeloma
Antibody with Potential to Treat Multiple Myeloma
Potential Treatment for Cystic Fibrosis Patients Infected with
Mycobacterium abscessus
Genetic Variants to Improve Treatment of Non-small Cell Lung
Cancer

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Orphan Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 2: World Historic Review for Orphan Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Orphan Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Biologics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 5: World Historic Review for Biologics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for Biologics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Non-Biologics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 8: World Historic Review for Non-Biologics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 9: World 16-Year Perspective for Non-Biologics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 11: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 12: World 16-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Hematology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 14: World Historic Review for Hematology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Hematology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Neurology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 17: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Cardiovascular by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 20: World Historic Review for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 21: World 16-Year Perspective for Cardiovascular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Other Disease Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 23: World Historic Review for Other Disease Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 24: World 16-Year Perspective for Other Disease Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Endocrinology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 26: World Historic Review for Endocrinology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Endocrinology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for
Respiratory by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 29: World Historic Review for Respiratory by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 30: World 16-Year Perspective for Respiratory by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 31: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 32: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 33: World 16-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 34: World Orphan Drugs Market Analysis of Annual Sales in
US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2023 (E)
Table 35: USA Recent Past, Current & Future Analysis for Orphan
Drugs by Drug Type - Biologics and Non-Biologics - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 36: USA Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 37: USA 16-Year Perspective for Orphan Drugs by Drug Type -
Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 38: USA Recent Past, Current & Future Analysis for Orphan
Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 39: USA Historic Review for Orphan Drugs by Disease Type -
Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 40: USA 16-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

CANADA
Table 41: Canada Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: Canada Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 43: Canada 16-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 44: Canada Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 45: Canada Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 46: Canada 16-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

JAPAN
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2023 (E)
Table 47: Japan Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 48: Japan Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 49: Japan 16-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 50: Japan Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 51: Japan Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 52: Japan 16-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

CHINA
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2023 (E)
Table 53: China Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 54: China Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 55: China 16-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 56: China Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 57: China Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 58: China 16-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

EUROPE
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2023 (E)
Table 59: Europe Recent Past, Current & Future Analysis for
Orphan Drugs by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 60: Europe Historic Review for Orphan Drugs by Geographic
Region - France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 61: Europe 16-Year Perspective for Orphan Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2014, 2023 & 2030

Table 62: Europe Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 63: Europe Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 64: Europe 16-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 65: Europe Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 66: Europe Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 67: Europe 16-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

FRANCE
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2023 (E)
Table 68: France Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 69: France Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 70: France 16-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 71: France Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 72: France Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 73: France 16-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

GERMANY
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2023 (E)
Table 74: Germany Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 75: Germany Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 76: Germany 16-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 77: Germany Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 78: Germany Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 79: Germany 16-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

ITALY
Table 80: Italy Recent Past, Current & Future Analysis for
Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: Italy Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 82: Italy 16-Year Perspective for Orphan Drugs by Drug
Type - Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 83: Italy Recent Past, Current & Future Analysis for
Orphan Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 84: Italy Historic Review for Orphan Drugs by Disease
Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 85: Italy 16-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

UNITED KINGDOM
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2023 (E)
Table 86: UK Recent Past, Current & Future Analysis for Orphan
Drugs by Drug Type - Biologics and Non-Biologics - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 87: UK Historic Review for Orphan Drugs by Drug Type -
Biologics and Non-Biologics Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 88: UK 16-Year Perspective for Orphan Drugs by Drug Type -
Percentage Breakdown of Value Sales for Biologics and
Non-Biologics for the Years 2014, 2023 & 2030

Table 89: UK Recent Past, Current & Future Analysis for Orphan
Drugs by Disease Type - Oncology, Hematology, Neurology,
Endocrinology, Cardiovascular, Respiratory, Immunotherapy and
Other Disease Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 90: UK Historic Review for Orphan Drugs by Disease Type -
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 91: UK 16-Year Perspective for Orphan Drugs by Disease
Type - Percentage Breakdown of Value Sales for Oncology,
Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

REST OF EUROPE
Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: Rest of Europe Historic Review for Orphan Drugs by
Drug Type - Biologics and Non-Biologics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 94: Rest of Europe 16-Year Perspective for Orphan Drugs
by Drug Type - Percentage Breakdown of Value Sales for
Biologics and Non-Biologics for the Years 2014, 2023 & 2030

Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Orphan Drugs by Disease Type - Oncology, Hematology,
Neurology, Endocrinology, Cardiovascular, Respiratory,
Immunotherapy and Other Disease Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 96: Rest of Europe Historic Review for Orphan Drugs by
Disease Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 97: Rest of Europe 16-Year Perspective for Orphan Drugs
by Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

ASIA-PACIFIC
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Asia-Pacific for 2023 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 99: Asia-Pacific Historic Review for Orphan Drugs by Drug
Type - Biologics and Non-Biologics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 100: Asia-Pacific 16-Year Perspective for Orphan Drugs by
Drug Type - Percentage Breakdown of Value Sales for Biologics
and Non-Biologics for the Years 2014, 2023 & 2030

Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Orphan Drugs by Disease Type - Oncology, Hematology,
Neurology, Endocrinology, Cardiovascular, Respiratory,
Immunotherapy and Other Disease Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 102: Asia-Pacific Historic Review for Orphan Drugs by
Disease Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 103: Asia-Pacific 16-Year Perspective for Orphan Drugs by
Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

REST OF WORLD
Table 104: Rest of World Recent Past, Current & Future Analysis
for Orphan Drugs by Drug Type - Biologics and Non-Biologics -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 105: Rest of World Historic Review for Orphan Drugs by
Drug Type - Biologics and Non-Biologics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 106: Rest of World 16-Year Perspective for Orphan Drugs
by Drug Type - Percentage Breakdown of Value Sales for
Biologics and Non-Biologics for the Years 2014, 2023 & 2030

Table 107: Rest of World Recent Past, Current & Future Analysis
for Orphan Drugs by Disease Type - Oncology, Hematology,
Neurology, Endocrinology, Cardiovascular, Respiratory,
Immunotherapy and Other Disease Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 108: Rest of World Historic Review for Orphan Drugs by
Disease Type - Oncology, Hematology, Neurology, Endocrinology,
Cardiovascular, Respiratory, Immunotherapy and Other Disease
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 109: Rest of World 16-Year Perspective for Orphan Drugs
by Disease Type - Percentage Breakdown of Value Sales for
Oncology, Hematology, Neurology, Endocrinology, Cardiovascular,
Respiratory, Immunotherapy and Other Disease Types for the
Years 2014, 2023 & 2030

IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06051495/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

 

            











    

        

        
Contact Data

        


    
    

 
    



        

        
            GlobeNewswire